A Phase 2/3 Adaptive Double-blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Adult and Pediatric subjects With APOL1-mediated Proteinuric Kidney Disease
Brief description of study
This is an adaptive Phase 2/3 study of VX-147 in subjects Adult and Pediatric with APOL1-mediated proteinuric kidney disease that is designed to select a dose of VX-147 and establish the efficacy and safety of the selected dose
Clinical Study Identifier: s22-01371
ClinicalTrials.gov Identifier: NCT05312879
Principal Investigator:
David Michael Charytan.
Other Investigators:
Laura Malaga-Dieguez,
Linda X Wang,
David T Liu,
Marissa Lipton,
Nina J Caplin.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.